Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-23T10:43:20.425Z Has data issue: false hasContentIssue false

9 - Apomorphine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Apokyn, Apo-go, Uprima

Generic?

• No

Class

• Antiparkinson agent

Commonly Prescribed for

(FDA approved in bold)

Parkinson's disease (PD): acute intermittent treatment of “off” episodes

How the Drug Works

• It is a dopamine partial agonist to D2-4 receptors. D2 agonism is likely the main reason for effectiveness in PD. Despite its name, does not actually contain morphine or act on morphine receptors

How Long Until It Works

• PD: 10–60 minutes

If It Works

• PD: this is an adjunctive medication designed for use with other PD treatments. Continue to adjust other PD treatments to achieve maximum functionality

If It Doesn't Work

• PD: adjust PD medication regimen, determine compliance with medications, and reconsider the diagnosis

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Patients requiring frequent injections will need an improved treatment plan to avoid severe “off” periods. Strategies include shortening the interval of levodopa dosing, adding catechol-O-methyltransferase (COMT) inhibitors, or adding longer-acting dopamine agonists

Tests

• None required

How the Drug Causes AEs

• Direct effect on dopamine receptors

Notable AEs

• Injection site reactions, drowsiness, nausea or vomiting, dizziness, postural hypotension, hallucinations, edema. Less common hypersexuality or erections

Life-Threatening or Dangerous AEs

• May cause somnolence or sudden-onset sleep. Severe orthostatic hypotension and nausea/vomiting, even when compared to other PD treatments

Weight Gain

• Unusual

Sedation

• Common

What to Do About AEs

• Orthostatic hypotension: the first dose should be given in a monitored setting (such as a physician's office). Check supine and standing blood pressure predose and 20, 40, and 60 minutes after injection. If there is no clinical improvement and no AEs, a dose of 4mg can be given, no earlier than 2 hours after the initial dose

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 32 - 34
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Apomorphine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.010
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Apomorphine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.010
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Apomorphine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.010
Available formats
×